Publication | Open Access
OA04.02 CheckMate 817: First-Line Nivolumab + Ipilimumab in Patients with ECOG PS 2 and Other Special Populations with Advanced NSCLC
48
Citations
0
References
2019
Year
Advanced NsclcEcog Ps 2Therapeutic EfficacyPharmacotherapyMedicineOa04.02 Checkmate 817Epidemiology
No additional data available for this publication yet. Check back later!